DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 
MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with 
Advanced Cancer 
2021-01-25 / 22:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Media Release 
MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer 
PLANEGG/MUNICH, Germany and SHANGHAI, China - January 25, 2021 - MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & 
TecDAX; NASDAQ: MOR) and I-Mab (NASDAQ: IMAB) today announced that the first patient has been dosed in a phase 1 dose 
escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MOR210/ TJ210 
monotherapy in patients with relapsed or refractory advanced solid tumors in the United States. 
MOR210/TJ210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1 
(C5aR1). Produced in the tumoral microenvironment, its ligand C5a acts as a chemoattractant to recruit tumor-promoting 
cells such as myeloid-derived suppressor cells, M2 macrophages and neutrophils. MOR210/TJ210 is designed to induce 
anti-tumor properties by blocking the activation and migration of C5aR1-expressing myeloid cells. 
Preclinical studies have shown that targeting the C5aR-C5a axis exerts anti-tumor activity with immune checkpoint 
inhibitors. Furthermore, in vitro activity was observed for blocking the C5a/C5aR pathway also at very high C5a 
concentrations leading to a long duration of action. MOR210/TJ210 demonstrated a good safety profile with no observed 
adverse effects up to the highest dose tested in non-clinical safety studies. 
The phase 1 clinical trial is an open-label dose escalation study with multiple doses in multiple centers in the U.S. 
to evaluate the safety, tolerability, and PK/PD of MOR210/TJ210 in subjects with advanced solid tumors. The development 
program will evolve into further clinical combination studies of MOR210/TJ210 with checkpoint inhibitors. 
"We are encouraged by the data observed in the preclinical studies and believe that TJ210/MOR210 with its unique 
properties has great potential to target difficult-to-treat cancers," said Dr. Joan Shen, CEO of I-Mab. "The data 
generated from this study will provide valuable information about TJ210/MOR210's safety and tolerability profile and 
its potential benefits in patients with advanced cancers." 
"We look forward to progressing with MOR210/TJ210 into clinical studies together with I-Mab to investigate its 
potential as a novel therapeutic option for patients with advanced solid tumors," said Dr. Malte Peters, Chief Research 
& Development Officer of MorphoSys. 
MorphoSys will receive a USD1.5 million payment from I-Mab for achieving this milestone under the license agreement 
between the two companies. MorphoSys and I-Mab entered into an exclusive strategic collaboration and licensing 
agreement to develop and commercialize MOR210/TJ210 in November 2018. Under the terms of agreement, I-Mab receives 
exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains 
rights in other parts of the world. With support from MorphoSys, I-Mab will also fund and conduct all global 
development activities of MOR210/TJ210, including clinical trials in China and the U.S., towards clinical 
proof-of-concept (PoC) in oncology. 
About MOR210/TJ210 
MOR210/TJ210 is a novel human antibody directed against C5aR1 derived from MorphoSys's HuCAL Platinum^(R) technology. 
C5aR1, the receptor of the complement factor C5a, is investigated as a potential new drug target in the field of 
immuno-oncology and autoimmune diseases. Tumors have been shown to produce high amounts of C5a, which, by recruiting 
and activating myeloid-derived suppressor cells (MDSCs), M2 macrophages and neutrophils, is assumed to contribute to an 
immune-suppressive pro-tumorigenic microenvironment. MOR210/TJ210 is intended to block the interaction between C5a and 
its receptor, thereby potentially neutralizing the immune suppressive function of C5a and enabling immune cells to 
attack the tumor. 
HuCAL Platinum^(R) is a registered trademark of MorphoSys AG. 
About MorphoSys 
MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development 
and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases. Based on its 
leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed 
and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical 
development. In 2017, Tremfya^(R), developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, 
Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive 
regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of 
MorphoSys' proprietary product Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a 
certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. 
subsidiary MorphoSys US Inc., has more than 600 employees. More information at www.morphosys.com or 
www.morphosys-us.com. 
Monjuvi^(R) is a registered trademark of MorphoSys AG. 
Tremfya^(R) is a registered trademark of Janssen Biotech, Inc. 
About I-Mab 
I-Mab (NASDAQ: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and 
commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune diseases. The 
Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's 
globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal 
discovery and global partnerships for in-licensing, based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market 
development strategies. The Company is progressing from a clinical stage biotech company into a fully integrated global 
biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility and commercial 
capability. I-Mab has offices in Beijing, Shanghai, Hangzhou and Hong Kong in China, and Maryland and San Diego in the 
United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter 
and WeChat. 
MorphoSys Forward-Looking Statements 
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including 
the expectations regarding the further clinical development of MOR210/TJ210, interactions with regulatory authorities 
and expectations regarding regulatory filings and possible approvals for MOR210/TJ210 as well as the potential future 
commercialization of MOR210/TJ210. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," 
"predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to 
identify forward-looking statements, although not all forward-looking statements contain these identifying words. The 
forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and 
involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and 
liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic 
or future results, financial conditions and liquidity, performance or achievements expressed or implied by such 
forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, 
and the development of the industry in which it operates are consistent with such forward-looking statements, they may 
not be predictive of results or developments in future periods. Among the factors that may result in differences are 
MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' 
business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research 
activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug 
candidates, commercial supply of current or future approved products, and launching, marketing and selling current or 
future approved products, the global collaboration and license agreement for MOR210/TJ210, the further clinical 
development of MOR210/TJ210, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll 
patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding 
future regulatory filings , MorphoSys' reliance on collaborations with third parties, estimating the commercial 
potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual 
Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the 
reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements 
speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any 
such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any 
change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood 
that actual results will differ from those set forth in the forward-looking statements, unless specifically required by 
law or regulation. 
I-Mab Forward Looking Statements

(MORE TO FOLLOW) Dow Jones Newswires

January 25, 2021 16:01 ET (21:01 GMT)